Fusobacterium nucleatum in tumors: from tumorigenesis to tumor metastasis and tumor resistance
Cancer Biol Ther. 2024 Dec 31;25(1):2306676. doi: 10.1080/15384047.2024.2306676. Epub 2024 Jan 30.ABSTRACTFusobacterium nucleatum, an anaerobic Gram-negative bacterium primarily residing in the oral cavity, has garnered significant attention for its emerging role in cancer progression and prognosis. While extensive research has revealed mechanistic links between Fusobacterium nucleatum and colorectal cancer, a comprehensive review spanning its presence and metastatic implications in cancers beyond colorectal origin is conspicuously absent. This paper broadens our perspective from colorectal cancer to various malignancies a...
Source: Cancer Biology and Therapy - January 30, 2024 Category: Cancer & Oncology Authors: Chun Ye Xiao Liu Zilun Liu Chuxuan Pan Xiaowei Zhang Zhanyi Zhao Haitao Sun Source Type: research
The critical role of tumor microbiome in cancer immunotherapy
In conclusion, the potential of microbial immunotherapy to enhance treatment outcomes for cancer patients should not be underestimated. Through this review, it is hoped that more research on tumor microbial immunotherapy will be done to better solve the treatment problems of cancer patients.PMID:38241173 | PMC:PMC10802201 | DOI:10.1080/15384047.2024.2301801 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - January 19, 2024 Category: Cancer & Oncology Authors: Liu Yang Qi Wang Lijuan He Xingyu Sun Source Type: research
The facilitating effects of KRT80 on chemoresistance, lipogenesis, and invasion of esophageal cancer
Cancer Biol Ther. 2024 Dec 31;25(1):2302162. doi: 10.1080/15384047.2024.2302162. Epub 2024 Jan 19.ABSTRACTKeratin 80 (KRT80) is a filament protein that makes up one of the major structural fibers of epithelial cells, and involved in cell differentiation and epithelial barrier integrity. Here, KRT80 mRNA expression was found to be higher in esophageal cancer than normal epithelium by RT-PCR and bioinformatics analysis (p < .05), opposite to KRT80 methylation (p < .05). There was a negative relationship between promoter methylation and expression level of KRT80 gene in esophageal cancer (p < .05). KRT80 mRNA express...
Source: Cancer Biology and Therapy - January 19, 2024 Category: Cancer & Oncology Authors: Wen-Jing Yun Jun Li Nan-Chang Yin Cong-Yu Zhang Zheng-Guo Cui Li Zhang Hua-Chuan Zheng Source Type: research
Mutually exclusive teams-like patterns of gene regulation characterize phenotypic heterogeneity along the noradrenergic-mesenchymal axis in neuroblastoma
Cancer Biol Ther. 2024 Dec 31;25(1):2301802. doi: 10.1080/15384047.2024.2301802. Epub 2024 Jan 17.ABSTRACTNeuroblastoma is the most frequent extracranial pediatric tumor and leads to 15% of all cancer-related deaths in children. Tumor relapse and therapy resistance in neuroblastoma are driven by phenotypic plasticity and heterogeneity between noradrenergic (NOR) and mesenchymal (MES) cell states. Despite the importance of this phenotypic plasticity, the dynamics and molecular patterns associated with these bidirectional cell-state transitions remain relatively poorly understood. Here, we analyze multiple RNA-seq datasets a...
Source: Cancer Biology and Therapy - January 17, 2024 Category: Cancer & Oncology Authors: Manas Sehgal Sonali Priyadarshini Nayak Sarthak Sahoo Jason A Somarelli Mohit Kumar Jolly Source Type: research
Epigenetic silencing < em > ZSCAN23 < /em > promotes pancreatic cancer growth by activating Wnt signaling
In this study, we explored the epigenetic regulation and the function of ZSCAN23 in PDAC. ZSCAN23 was methylated in 60.21% (171/284) of PDAC and its expression was regulated by promoter region methylation. The expression of ZSCAN23 inhibited cell proliferation, colony formation, migration, invasion, and induced apoptosis and G1/S phase arrest. ZSCAN23 suppressed Panc10.05 cell xenograft growth in mice. Mechanistically, ZSCAN23 inhibited Wnt signaling by interacting with myosin heavy chain 9 (MYH9) in pancreatic cancer cells. ZSCAN23 is frequently methylated in PDAC and may serve as a detective marker. ZSCAN23 suppresses PD...
Source: Cancer Biology and Therapy - January 16, 2024 Category: Cancer & Oncology Authors: Qian Du Meiying Zhang Aiai Gao Tao He Mingzhou Guo Source Type: research
Hypoxia promotes non-small cell lung cancer cell stemness, migration, and invasion via promoting glycolysis by lactylation of SOX9
CONCLUSION: Hypoxia induced the lactylation of SOX9 to promote stemness, migration, and invasion via promoting glycolysis. The findings suggested that targeting hypoxia may be an effective way for NSCLC treatment and reveal a new mechanism of hypoxia in NSCLC.PMID:38226837 | PMC:PMC10793688 | DOI:10.1080/15384047.2024.2304161 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - January 16, 2024 Category: Cancer & Oncology Authors: Fei Yan Yue Teng Xiaoyou Li Yuejiao Zhong Chunyi Li Feng Yan Xia He Source Type: research
Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models
Cancer Biol Ther. 2024 Dec 31;25(1):2296048. doi: 10.1080/15384047.2023.2296048. Epub 2024 Jan 11.ABSTRACTCD73 is a cell surface 5'nucleotidase (NT5E) and key node in the catabolic process generating immunosuppressive adenosine in cancer. Using a murine monoclonal antibody surrogate of Oleclumab, we investigated the effect of CD73 inhibition in concert with cytotoxic therapies (chemotherapies as well as fractionated radiotherapy) and PD-L1 blockade. Our results highlight improved survival in syngeneic tumor models of colorectal cancer (CT26 and MC38) and sarcoma (MCA205). This therapeutic outcome was in part driven by cyto...
Source: Cancer Biology and Therapy - January 11, 2024 Category: Cancer & Oncology Authors: Brajesh P Kaistha Gozde Kar Andreas Dannhorn Amanda Watkins Grace Opoku-Ansah Kristina Ilieva Stefanie Mullins Judith Anderton Elena Galvani Fabien Garcon Jean-Martin Lapointe Lee Brown James Hair Tim Slidel Nadia Luheshi Kelli Ryan Elizabeth Hardaker Sim Source Type: research
WYC-209 inhibited GC malignant progression by down-regulating WNT4 through RAR α
Cancer Biol Ther. 2024 Dec 31;25(1):2299288. doi: 10.1080/15384047.2023.2299288. Epub 2024 Jan 4.ABSTRACTGastric cancer (GC) has been a major health burden all over the world but there are fewer promising chemotherapeutic drugs due to its multidrug resistance. It has been reported that WYC-209 suppresses the growth and metastasis of tumor-repopulating cells but the effect on GC was not explored. MTT, colony formation, and transwell assays were performed to examine the effects of WYC-209 on the proliferation, colony growth, and mobility of GC cells. Western blotting and qRT-PCR were used to detect the expression of proteins...
Source: Cancer Biology and Therapy - January 5, 2024 Category: Cancer & Oncology Authors: Zhenyuan Qian Wenfa Lin Xufan Cai Jianzhang Wu Kun Ke Zaiyuan Ye Fang Wu Source Type: research
WYC-209 inhibited GC malignant progression by down-regulating WNT4 through RAR α
Cancer Biol Ther. 2024 Dec 31;25(1):2299288. doi: 10.1080/15384047.2023.2299288. Epub 2024 Jan 4.ABSTRACTGastric cancer (GC) has been a major health burden all over the world but there are fewer promising chemotherapeutic drugs due to its multidrug resistance. It has been reported that WYC-209 suppresses the growth and metastasis of tumor-repopulating cells but the effect on GC was not explored. MTT, colony formation, and transwell assays were performed to examine the effects of WYC-209 on the proliferation, colony growth, and mobility of GC cells. Western blotting and qRT-PCR were used to detect the expression of proteins...
Source: Cancer Biology and Therapy - January 5, 2024 Category: Cancer & Oncology Authors: Zhenyuan Qian Wenfa Lin Xufan Cai Jianzhang Wu Kun Ke Zaiyuan Ye Fang Wu Source Type: research
WYC-209 inhibited GC malignant progression by down-regulating WNT4 through RAR α
Cancer Biol Ther. 2024 Dec 31;25(1):2299288. doi: 10.1080/15384047.2023.2299288. Epub 2024 Jan 4.ABSTRACTGastric cancer (GC) has been a major health burden all over the world but there are fewer promising chemotherapeutic drugs due to its multidrug resistance. It has been reported that WYC-209 suppresses the growth and metastasis of tumor-repopulating cells but the effect on GC was not explored. MTT, colony formation, and transwell assays were performed to examine the effects of WYC-209 on the proliferation, colony growth, and mobility of GC cells. Western blotting and qRT-PCR were used to detect the expression of proteins...
Source: Cancer Biology and Therapy - January 5, 2024 Category: Cancer & Oncology Authors: Zhenyuan Qian Wenfa Lin Xufan Cai Jianzhang Wu Kun Ke Zaiyuan Ye Fang Wu Source Type: research
WYC-209 inhibited GC malignant progression by down-regulating WNT4 through RAR α
Cancer Biol Ther. 2024 Dec 31;25(1):2299288. doi: 10.1080/15384047.2023.2299288. Epub 2024 Jan 4.ABSTRACTGastric cancer (GC) has been a major health burden all over the world but there are fewer promising chemotherapeutic drugs due to its multidrug resistance. It has been reported that WYC-209 suppresses the growth and metastasis of tumor-repopulating cells but the effect on GC was not explored. MTT, colony formation, and transwell assays were performed to examine the effects of WYC-209 on the proliferation, colony growth, and mobility of GC cells. Western blotting and qRT-PCR were used to detect the expression of proteins...
Source: Cancer Biology and Therapy - January 5, 2024 Category: Cancer & Oncology Authors: Zhenyuan Qian Wenfa Lin Xufan Cai Jianzhang Wu Kun Ke Zaiyuan Ye Fang Wu Source Type: research
Correction
Cancer Biol Ther. 2024 Dec 31;25(1):2299054. doi: 10.1080/15384047.2024.2299054. Epub 2023 Dec 26.NO ABSTRACTPMID:38146637 | PMC:PMC10761110 | DOI:10.1080/15384047.2024.2299054 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - December 26, 2023 Category: Cancer & Oncology Source Type: research
Correction
Cancer Biol Ther. 2024 Dec 31;25(1):2299054. doi: 10.1080/15384047.2024.2299054. Epub 2023 Dec 26.NO ABSTRACTPMID:38146637 | PMC:PMC10761110 | DOI:10.1080/15384047.2024.2299054 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - December 26, 2023 Category: Cancer & Oncology Source Type: research
Correction
Cancer Biol Ther. 2024 Dec 31;25(1):2299054. doi: 10.1080/15384047.2024.2299054. Epub 2023 Dec 26.NO ABSTRACTPMID:38146637 | DOI:10.1080/15384047.2024.2299054 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - December 26, 2023 Category: Cancer & Oncology Source Type: research
Correction
Cancer Biol Ther. 2024 Dec 31;25(1):2299054. doi: 10.1080/15384047.2024.2299054. Epub 2023 Dec 26.NO ABSTRACTPMID:38146637 | DOI:10.1080/15384047.2024.2299054 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - December 26, 2023 Category: Cancer & Oncology Source Type: research
